Cambrian’s ATX-304 mimics exercise, after GLP-1s left patients with frail muscle

Weight loss without muscle loss sounds like science fiction. But the real tension in obesity medicine is more blunt: GLP-1 drugs can help people shed weight, and they can also leave some patients “frail,” with dangerous muscle loss. That tradeoff is now driving a new wave of drug development aimed at a single outcome that investors, clinicians, and payers all care about: more fat loss, less lean-mass damage.

On Friday, New York-based Cambrian Biotech, a late-stage VC-backed pharmaceutical company, released early results from the first human study of ATX-304, a drug it describes as mimicking exercise. Cambrian’s CEO James Peyer told Business Insider that taking the pill is “like running 5-10k every day, metabolically speaking,” without the “sweaty mess.” The company’s stated target is not appetite reduction like GLP-1s, but a higher burn of daily calories, designed to “incinerate more calories every day” and shift how the body uses stored fuel.

To understand why this matters, you have to start with how GLP-1s work and why muscle got caught in the crossfire. GLP-1 medications like Ozempic, Mounjaro, and Zepbound reduce appetite and slow digestion. That’s part of why they work. But when patients eat less and lose weight quickly, the body still needs energy, and it often compensates by using more than fat. That can mean muscle loss, and faster weight loss often worsens that. Clinicians worry about the downstream consequences: frailty, weaker bones, and a general loss of functional capacity.

Now add a second layer. When someone is eating less on a GLP-1, muscle-building becomes even harder, because muscle growth requires enough protein and calories. So the issue is not just that muscle can be lost during weight loss. It is also that rebuilding can be harder while the diet side of the equation is constrained by the drug. That is why doctors who view GLP-1s as “game-changers for metabolic disease” still hesitate in cases where muscle loss could tip someone into a more fragile state.

Cambrian’s pitch is that ATX-304 is a different tool. Peyer says the goal is to increase metabolic rate, make fat “metabolically active,” and get muscles to burn more energy. Unlike GLP-1 drugs that dampen appetite and slow digestion, ATX-304 is designed to turn up energy use rather than simply change intake. The company presented early safety and signal data for 23 adults at an American Diabetes Association conference earlier this month. In that small initial safety trial, prediabetic patients with obesity taking the once-daily pill increased their resting metabolic rate and lost about 5% of visceral fat, described as the inflammatory kind that hugs internal organs and is linked to more chronic disease.

But even if the concept is compelling, executives know the real question is clinical proof, not metabolic vibes. Cambrian’s midsize trial, intended to give a clearer picture of what ATX-304 can do, is slated to read out at the end of 2027. That timeline matters for boards and capital allocators, because the upside is large but the validation steps are not optional. One early study cannot settle whether the drug meaningfully prevents functional decline, improves strength, improves walking speed, or reduces fall risk. Those are the kinds of outcomes end up driving acceptance, especially for older adults and for broader, long-term chronic use.

This isn’t happening in isolation. The broader industry is also chasing ways to preserve lean mass while weight drops. There is bimagrumab, a molecule designed to promote fat loss while preserving muscle, made by startup Versanis and acquired by Eli Lilly for $1.9 billion in 2023. There is SPX-001, which is intended to preserve lean mass while taking a GLP-1, acquired by AstraZeneca for about $300 million in 2025. And Novo Nordisk is counting on CagriSema, its next-generation GLP-1 combination, which the company hopes will help patients lose more fat and retain more muscle than Ozempic did.

What makes this surge feel strategically different is the willingness to revisit failures. Bimagrumab started as a failed muscle-wasting drug for sarcopenia, older people losing muscle with age. In large-scale trials run by Novartis from 2014 to 2018, it did not work. Versanis founder and serial biotech entrepreneur Lloyd Klickstein told Business Insider that they had “blinders on with respect to what muscle does,” focusing on muscle as strength rather than on its metabolic role. Investors reframed the goal toward recycling and maintaining muscle. In Eli Lilly’s latest trial of bimagrumab, which included over 500 people with obesity, adding it to an Ozempic prescription led those participants to lose an average of more than 90% of their body fat. For context, the source notes that scientists measuring weight loss have typically seen people lose roughly 65-75% fat and about 25-35% lean mass.

Other combination bets look less revolutionary but still aim at the same tradeoff. Novo Nordisk’s CagriSema, described as a combination of Ozempic and cagrilintide, netted 67% fat loss in patients with obesity. And beyond GLP-1 and monoclonal approaches, the market is also hearing a louder debate about where these therapies fit. Daniel Drucker, an endocrinologist at the University of Toronto who was instrumental in discovering GLP-1’s role in diabetes, told Business Insider, “No one is going to write a prescription for body composition changes.” Drucker wants drugs that directly and successfully target sarcopenia for the “hundreds of millions of older people who are frail and fragile.” His skepticism points to the gap between mechanism and clinically meaningful outcomes.

For executives watching this space, the second-order stakes are clear. If these new muscle-preserving or exercise-mimicking therapies can prove real-world functional benefits, they could reshape prescribing patterns and payer coverage decisions, potentially turning obesity drugs from purely weight-loss products into longer-term metabolic health tools. If they fail to show outcomes like fewer falls or improved strength, the field could remain trapped in promises that do not convert into prescriptions. Cambrian’s ATX-304 is currently a signal, not a verdict. But it is a direct attempt to rewrite the one thing doctors have been forced to tolerate with GLP-1s: muscle loss on the way down.